Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Trial Profile

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumasiran (Primary)
  • Indications Primary hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE-A
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 10 Jan 2020 According to an Alnylam Pharmaceuticals media release, the company looks forward to working with the FDA to advance this medicine to patients and anticipate receiving approval in late 2020.
    • 10 Jan 2020 According to an Alnylam Pharmaceuticals media release, Alnylam initiates rolling submission of NDA for Lumasiran in primary Hyperoxaluria Type 1. Alnylam has submitted the non-clinical components to the FDA and expects to submit the remaining components in early 2020.
    • 17 Dec 2019 According to an Alnylam Pharmaceuticals media release, the company will be present full results from this study in an oral plenary session on 31 March 2020 at OxalEurope International Congress in Amsterdam.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top